Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT 2) receptor

British Journal of Pharmacology

Volumn 160, Issue 2, 2010, Pages 399-409

  Wunder, F ^a   Tinel, H ^a   Kast, R ^a   Geerts, A ^a   Becker, Em ^a   Kolkhof, P ^a   Hutter J ^a   Erguden J ^a   Harter M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

CysLT 1 receptor; CysLT 2 receptor; CysLT 2 receptor antagonist; Cysteinyl leukotrienes

Indexed keywords

3 [[(3 CARBOXYCYCLOHEXYL)AMINO]CARBONY] 4 [3 [4 [4 (CYCLOHEXYLOXY)BUTOXY]PHENYL]PROPOXY]BENZOIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; HAMI 3379; LEUKOTRIENE 1 RECEPTOR; LEUKOTRIENE 2 RECEPTOR; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG POTENCY; DRUG STRUCTURE; GUINEA PIG; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE CONTRACTILITY; IC 50; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEART; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE C4; LEUKOTRIENE D4; MALE; MYOCARDIAL CONTRACTION; PHTHALIC ACIDS; PROTEIN BINDING; RECEPTORS, LEUKOTRIENE; TOSYL COMPOUNDS;

EID: 77951683063     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00730.x     Document Type: Article

References (43)

1. Alexander S, Mathie A, Peters J (2009). Guide to receptors and channels (GRAC), 4th edition (2009 revision). Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Allen SP, Dashwood MR, Chester AH, Tadjkarimi S, Collins M, Piper PJ et al 1993). Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. Cardioscience 4 : 47 54. (Pubitemid 23147341)
3. Allen S, Dashwood M, Morrison K, Yacoub M (1998). Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97 : 2406 2413. (Pubitemid 28278184)
4. Bäck M (2009). Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 23 : 41 48.
5. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y (2004). Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 279 : 46129 46134. (Pubitemid 39491607)
6. 4: effects on human and guinea pig cardiac preparations in vitro. J Pharmacol Exp Ther 221 : 235 241. (Pubitemid 12156497)
7. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE (2007). Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 27 : 469 527. (Pubitemid 46984658)
8. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P (1992). Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85 : 230 236.
9. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D et al 2006). The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 25 : 4615 46127. (Pubitemid 44498134)
10. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL et al 1995). Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 23 : 283 285.
11. Drazen JM, Israel E, O'Byrne MB (1999). Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340 : 197 206. (Pubitemid 29063217)
12. Fauler J, Frölich JC (1989). Cardiovascular effects of leukotrienes. Cardiovasc Drugs Ther 3 : 499 505. (Pubitemid 19262250)
13. Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A (2000). Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med 161 : S112 S116. (Pubitemid 30129427)
14. Frey EA, Nicholson DW, Metters KM (1993). Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. Eur J Pharmacol 244 : 239 250.
15. Funk CD (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 : 1871 1875.
16. Funk CD (2005). Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4 : 664 672. (Pubitemid 41149760)
17. Härter M, Ergüden J, Wunder F, Tinel H, Köbberling J, Becker EM et al 2004). Isophthalic acid derivatives. Patent WO-2004052839-A 2004-06-24.
18. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS et al 2000). Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 : 30531 30536.
19. Helgadottir A, Manolescum A, Thorleifssonm G, Gretarsdottirm S, Jonsdottirm H, Thorsteinsdottir U et al 2004). The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 : 233 239. (Pubitemid 38282747)
20. Hui Y, Cheng Y, Smalera I, Jian W, Goldhahn L, Fitzgerald GA et al 2004). Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110 : 3360 3366. (Pubitemid 39557500)
21. Hui Y, Yang G, Galczenski H, Figueroa DJ, Austin CP, Copeland NG et al 2001). The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 276 : 47489 47495. (Pubitemid 37373132)
22. Jiang W, Hall SR, Moos MP, Cao RY, Ishii S, Ogunyankin KO et al 2008). Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 172 : 592 602. (Pubitemid 351354533)
23. Kamohara M, Takasaki J, Matsumoto M, Matsumoto Si, Saito T, Soga T et al 2001). Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun 287 : 1088 1092. (Pubitemid 32980563)
24. Kanaoka Y, Boyce JA (2004). Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173 : 1503 1510. (Pubitemid 38971578)
25. Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW et al 1990). The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 141 : 978 987. (Pubitemid 20157729)
26. Labat C, Ortiz JL, Norel X, Gorenne I, Verley J, Abram TS et al 1992). A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 263 : 800 805.
27. Letts LG (1987). Leukotrienes: role in cardiovascular physiology. Cardiovasc Clin 18 : 101 113.
28. Letts LG, Piper PJ (1982). The actions of leukotrienes C4 and D4 on guinea-pig isolated hearts. Br J Pharmacol 76 : 169 176.
29. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM et al 1999). Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 : 789 793. (Pubitemid 29293175)
30. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y (2009). GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A 106 : 11685 11690.
31. Maekawa A, Kanaoka Y, Xing W, Austen KF (2008). Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105 : 16695 16700.
32. McLeod JD, Piper PJ (1991). Effect of ICI 198,615, SK+F 104,353, MK-571 and CGP45715A on cysteinyl leukotriene-induced responses in guinea-pig heart. Prostaglandins 41 : 395 406.
33. Moos MP, Mewburn JD, Kan FW, Ishii S, Abe M, Sakimura K et al 2008). Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 22 : 4352 4362.
34. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O (2000). Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58 : 1601 1608.
35. Ogasawara H, Ishii S, Yokomizo T, Kakinuma T, Komine M, Tamaki K et al 2002). Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. J Biol Chem 277 : 18763 18768. (Pubitemid 34952434)
36. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N (2007). Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 14 : 1966 1977. (Pubitemid 47209107)
37. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ et al 1999). Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56 : 657 663. (Pubitemid 29406893)
38. Sharma JN, Mohammed LA (2006). The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 14 : 10 16.
39. Sjöström M, Johansson AS, Schröder O, Qiu H, Palmblad J, Haeggström JZ (2003). Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 23 : e37 e41.
40. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K et al 2003). Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 100 : 1238 1243. (Pubitemid 36183986)
41. 2 receptor. Biochem Biophys Res Commun 274 : 316 322. (Pubitemid 30614317)
42. Takase B, Kurita A, Maruyama T, Uehata A, Nishioka T, Mizuno K et al 1996). Change of plasma leukotriene C4 during myocardial ischemia in humans. Clin Cardiol 19 : 198 204. (Pubitemid 26314330)
43. Tudhope SR, Cuthbert NJ, Abram TS, Jennings MA, Maxey RJ, Thompson AM et al 1994). BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol 264 : 317 323.